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Abstract
Background: Asenapine demonstrated superiority over placebo for mania in bipolar I disorder patients
experiencing acute current manic or mixed episodes in 2 randomized, placebo-and olanzapine-controlled trials. We
report the results of exploratory pooled post hoc analyses from these trials evaluating asenapine’s effects on
depressive symptoms in patients from these trials with significant baseline depressive symptoms.
Methods: In the original trials (A7501004 [NCT00159744], A7501005 [NCT00159796]), 977 patients were randomized
to flexible-dose sublingual asenapine (10 mg twice daily on day 1; 5 or 10 mg twice daily thereafter), placebo, or
oral olanzapine 5-20 mg once daily for 3 weeks. Three populations were defined using baseline depressive
symptoms: (1) Montgomery-Asberg Depression Rating Scale (MADRS) total score ≥20 (n = 132); (2) Clinical Global
Impression for Bipolar Disorder-Depression (CGI-BP-D) scale severity score ≥4 (n = 170); (3) diagnosis of mixed
episodes (n = 302) by investigative site screening. For each population, asenapine and olanzapine were
independently compared with placebo using least squares mean change from baseline on depressive symptom
measures.
Results: Decreases in MADRS total score were statistically greater with asenapine versus placebo at days 7 and 21
in all populations; differences between olanzapine and placebo were not significant. Decreases in CGI-BP-D score
were significantly greater with asenapine versus placebo at day 7 in all categories and day 21 in population 1; CGI-
BP-D score reductions were significantly greater with olanzapine versus placebo at day 21 in population 1 and day
7 in populations 2 and 3.
Conclusions: These post hoc analyses show that asenapine reduced depressive symptoms in bipolar I disorder
patients experiencing acute manic or mixed episodes with clinically relevant depressive symptoms at baseline;
olanzapine results appeared to be less consistent. Controlled studies of asenapine in patients with acute bipolar
depression are necessary to confirm the generalizability of these findings.
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Background
Bipolar disorder is a serious chronic medical condition
that typically is cyclical, characterized by manic/hypo-
manic, depressed, or mixed states, and associated with a
high risk for suicide [1,2]. Although manic episodes are
considered the hallmark state of bipolar I disorder,
patients spend up to 4 times more symptomatic time in
depressed states [3], and it is depression that primarily
contributes to functional disability and high rates of sui-
cide [4-6]. In 2001, the World Health Organization
reported that bipolar affective disorders rank within the
top 10 causes of disability among all medical conditions,
as measured in years lived with disability [7].
Although a number of treatment options have been
established for acute manic or mixed episodes, including
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r o b u s te m p i r i c a ld a t as u p p o r t i v eo fe f f i c a c yf o ra c u t e
bipolar depression. To date, 2 atypical antipsychotics
have received regulatory approval for treatment of bipo-
lar depression. Quetiapine is approved as monotherapy
in the United States and European Union for treatment
of depressive episodes associated with bipolar disorder
[8] and an olanzapine-fluoxetine combination is
approved in the United States for the same indication
[9]. The adverse events, such as sedation and weight
gain, associated with these drugs and the fact that not
every patient responds equally well to treatment under-
score the need to investigate additional treatment
options.
Asenapine is an antipsychotic with a unique pharma-
cologic profile [10] indicated in the United States in
adults for treatment of schizophrenia and as monother-
apy or adjunctive therapy with lithium or valproate in
the treatment of manic or mixed episodes associated
with bipolar I disorder [11]. Asenapine is indicated in
the European Union for the treatment of moderate to
severe manic episodes associated with bipolar I disorder
[12]. The multireceptor pharmacologic profile of asena-
pine includes antagonism at serotonergic 5-HT2A and
adrenergic a2 receptors [10], suggesting that it may
effectively treat depressive symptoms. The potential effi-
cacy of asenapine against depressive symptoms is sup-
ported by preclinical findings in animal models [13].
In a pair of randomized placebo- and olanzapine-con-
trolled 3-week trials enrolling patients with bipolar I dis-
order experiencing a current manic or mixed episode,
asenapine demonstrated efficacy superior to placebo as
early as day 2 in the treatment of acute mania; the
active comparator in those studies (olanzapine) also
demonstrated superiority over placebo [14,15]. In a 9-
week extension of these trials, asenapine met criteria for
noninferiority to olanzapine in the treatment of mania
[16]. In a subsequent 40-week extension designed to
assess long-term safety and tolerability, asenapine was
well tolerated and maintained efficacy at a level compar-
able to olanzapine [17].
The current report describes an exploratory post hoc
analysis of the 2 aforementioned 3-week monotherapy
trials [14,15] undertaken to explore the effects of asena-
pine versus placebo on depressive symptoms in bipolar I
patients experiencing acute manic or mixed episodes.
Differences in the effects of asenapine versus olanzapine,
the active control from these studies, were also assessed.
Methods
Study design
Data from 2 multinational, 3-week, randomized, flexible-
dose, placebo- and olanzapine-controlled trials
(NCT00159744; NCT00159796) were included. Each
study was conducted in accordance with the principles
of Good Clinical Practice and was approved by the
appropriate institutional review boards and regulatory
agencies. The study design and patient populations have
been previously described [14,15]. In brief, the trials
were conducted in 10 countries (United States, India,
Russia, Ukraine, South Korea, Bulgaria, the Philippines,
Romania, Turkey, and Malaysia). Each study included
adult patients with a current Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition diagnosis of
manic or mixed episodes of bipolar I disorder. Included
patients were required to have a Young Mania Rating
Scale total score ≥20 at screening and baseline, a current
manic or mixed bipolar I episode that began ≤3 months
before screening, and a documented history of >1 mod-
erate to severe manic or mixed episode, with or without
psychotic features. Although limited doses of specific
benzodiazepines and sleep medications were allowed
during treatment week 1, all other psychotropic medica-
tions, including antidepressants, mood stabilizers, and
St. John’s wort, were prohibited [14,15].
Treatment
After single-blind placebo run-in periods of ≤7 days,
patients were randomly assigned to 3 weeks of sublin-
gual asenapine (10 mg twice daily [BID] on day 1, flex-
ible-dose 5 or 10 mg BID thereafter), placebo, or oral
olanzapine (15 mg once daily [QD] on day 1, flexible-
dose 5-20 mg QD thereafter) in a 2:1:2 ratio.
Post hoc assessment of depressive symptoms
For these analyses, patients were divided into 3 depres-
sion-related populations, each of which is considered to
denote clinically-relevant symptoms of depression:
￿ Baseline Montgomery-Asberg Depression Rating
Scale (MADRS) total score ≥20
￿ Baseline Clinical Global Impression for Bipolar
Disorder-Depression severity scale (CGI-BP-D)
severity score ≥4
￿ Baseline diagnosis of a mixed episode
Change from baseline on the above scales was evalu-
ated, as was the incidence of depression remission (ie,
percentage of patients with MADRS total score ≤12) for
each category on days 7 and 21.
In the primary trials, depression severity was assessed
using the MADRS, the Positive and Negative Syndrome
Scale (PANSS) Marder anxiety/depression factor, and
the CGI-BP-D scale. MADRS and PANSS Marder anxi-
ety/depression factor assessments were made on days 1,
7, and 21; the CGI-BP-D was administered at days 1, 2,
4, 7, 14, and 21. Baseline values were the last non-miss-
ing assessments on or prior to day 1 (randomization).
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Post hoc analyses were conducted for observed cases
data on selected visits, as well as study Endpoint/Day 21
(using last observation carried forward [LOCF] if miss-
ing data occurred), for each data set.
Data from patients in each of the 2 studies were pooled
for analysis; demographics and baseline MADRS and CGI-
BP-D scores were balanced between treatment groups.
Statistical analyses were conducted using an analysis of
covariance on observed cases, with baseline values used as
covariates; neither study nor the interaction of study ×
treatment effect were included as factors because no sig-
nificant differences were found between studies. For con-
tinuous measures (MADRS, CGI-BP-D, and PANSS
Marder anxiety/depression factor), comparisons were
made for asenapine versus placebo, olanzapine versus pla-
cebo, and asenapine versus olanzapine on treatment days
7 and 21 using the difference in least squares (LS) mean
change from baseline. Within-subject mean changes from
baseline on days 7 and 21 were assessed using t-tests.
Remission rate comparisons were made using Pearson
chi-square tests. All statistical tests were 2-tailed, with sta-
tistical significance set at P < 0.05 (trends are reported if
the P-values ranged from 0.05-0.09). No adjustments were
made for multiple comparisons.
Data are presented in Tables 1 and 2 as the arithmetic
mean ± SD and in all figures as the adjusted LS mean ±
SE; P-values are based on the LS mean differences for
between-group comparisons and arithmetic mean differ-
ences for within-subject changes.
Results
Study populations
The total number of randomized patients from the pri-
mary studies [14,15] included in the post hoc analyses
and their baseline demographic and clinical characteris-
tics are presented in Table 1. Of the 977 randomized
patients in the primary studies, 212 (22%) met post hoc
criteria for depression-related symptoms (MADRS ≥20
or CGI-BP-D ≥4) at baseline and 302 (31%) had a
mixed episode at baseline; 90 (9.2%) met criteria for
MADRS ≥20 or CGI-BP-D ≥4. Across groups, the per-
centages of patients meeting post hoc criteria for
depression-related symptoms (MADRS ≥20 or CGI-BP-
D ≥4) at baseline were 19% (72/379) for asenapine
(MADRS ≥20 and CGI-BP-D ≥4; 32 [8.4%]), 24% (49/
202) for placebo (MADRS ≥20 and CGI-BP-D ≥4; 21
[10.4%]), and 23% (91/396) for olanzapine (MADRS ≥20
and CGI-BP-D ≥4; 37 [9.3%]); for mixed episodes the
percentages were 29% (111/379) for asenapine, 33% (67/
202) for placebo, and 31% (124/396) for olanzapine.
Baseline demographic characteristics were generally
comparable across depression-related categories and
treatment groups (Table 1). In patients with mixed
episodes, the percentage of men in the placebo group
was slightly lower than in the asenapine or olanzapine
groups. The MADRS and CGI-BP-D severity scores
were comparable across groups within each depression-
related category. Patients experiencing mixed episodes
had the lowest MADRS total and CGI-BP-D severity
scores at baseline compared with those in other depres-
sion-related categories (Table 1).
The most common reasons for discontinuation across
all depression-related categories were adverse events and
withdrawn consent with asenapine, lack of efficacy and
withdrawn consent with placebo, and lack of efficacy
with olanzapine (Table 1).
Efficacy
Montgomery-Asberg Depression Rating Scale total score
In patients with baseline MADRS total scores ≥20, LS
mean ± SE changes from baseline in MADRS total score
with asenapine were significantly greater than placebo
on days 7 (-11.3 ± 1.5 vs -4.5 ± 1.6; P = 0.002) and 21
(-13.6 ± 1.6 vs-7.0 ± 1.8; P = 0.009) and were greater
than olanzapine on day 7 (-11.3 ± 1.5 vs -6.9 ± 1.2; P =
0.020). Change from baseline MADRS total score with
olanzapine was not statistically different from placebo
o nd a y7( - 6 . 9±1 . 2v s- 4 . 5±1 . 6 ;P =0 . 2 3 1 )o r2 1
(-10.6 ± 1.3 vs-7.0 ± 1.8; P = 0.121) (Figure 1A).
In patients with baseline CGI-BP-D severity scores ≥4,
LS mean ± SE changes in MADRS total score with ase-
napine were significantly greater than placebo on days 7
(-7.7 ± 1.1 vs -3.6 ± 1.4; P = 0.023) and 21 (-9.9 ± 1.3 vs
-5.4 ± 1.6; P = 0.030), with the difference from olanza-
pine showing a trend towards statistical significance on
day 7 (-7.7 ± 1.1 vs -5.3 ± 0.9; P = 0.088). Change from
baseline in MADRS total score with olanzapine was not
statistically different from placebo at day 7 (-5.3 ± 0.9 vs
-3.6 ± 1.4; P = 0.314), but it showed a trend towards
statistical significance on day 21 (-8.8 ± 1.0 vs -5.4 ±
1.6; P = 0.084) (Figure 1B).
In patients with a mixed episode at baseline, LS mean
± SE changes in MADRS total score were significantly
greater with asenapine than placebo on days 7 (-6.7 ±
0.7 vs -3.6 ± 1.0; P = 0.011) and 21 (-8.5 ± 0.8 vs -5.8 ±
1.1; P = 0.040), with the difference from olanzapine
showing a trend towards statistical significance on day 7
( - 6 . 7±0 . 7v s- 5 . 0±0 . 7 ;P = 0.076). Change from base-
line in MADRS total score with olanzapine was not sta-
tistically different from placebo on days 7 (-5.0 ± 0.7 vs
-3.6 ± 1.0; P = 0.244) or 21 (-7.2 ± 0.7 vs -5.8 ± 1.1; P =
0.269) (Figure 1C).
Mean ± SD changes from baseline in MADRS total
score are summarized in Table 2. In all treatment
groups and across all depression-related categories,
within-subject changes from baseline on days 7 and 21
were statistically significant.
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Page 3 of 16Table 1 Demographics, clinical characteristics, and disposition
Asenapine
(n = 379)*
Placebo
(n = 202)*
Olanzapine
(n = 396)*
Patient populations, n
Patients with mixed episodes
† 111 67 124
Patients with MADRS total score ≥20
‡ 45 33 54
Patients with CGI-BP-D severity score ≥4
§ 59 37 74
Men, n (%)
Patients with mixed episodes
† 63 (56.8) 30 (44.8) 70 (56.5)
Patients with MADRS total score≥20
‡ 22 (48.9) 16 (48.5) 26 (48.1)
Patients with CGI-BP-D severity score ≥4
§ 31 (52.5) 18 (48.6) 37 (50)
Mean ± SD age, y
Patients with mixed episodes
† 38.3 ± 11.2 39.5 ± 12.5 38.8 ± 10.4
Patients with MADRS total score ≥20
‡ 38.3 ± 11.5 41.2 ± 11.6 39.5 ± 11.1
Patients with CGI-BP-D severity score ≥4
§ 39.4 ± 11.8 36.9 ± 12.7 39.6 ± 9.7
Mean ± SD daily dose, mg
Patients with mixed episodes
† 18.2 ± 2.8 - 15.6 ± 2.3
Patients with MADRS total score ≥20
‡ 18.3 ± 2.7 - 16.3 ± 2.5
Patients with CGI-BP-D severity score ≥4
§ 17.9 ± 2.6 - 15.9 ± 2.5
Mean ± SD MADRS total score
Patients with mixed episodes
† 16.7 ± 6.3 18.8 ± 7.3 16.9 ± 6.9
Patients with MADRS total score ≥20
‡ 24.4 ± 3.5 25.8 ± 4.7 24.7 ± 4.4
Patients with CGI-BP-D severity score ≥4
§ 20.2 ± 6.9 22.2 ± 7.5 19.7 ± 7.2
Mean ± SD CGI-BP-D severity score
Patients with mixed episodes
† 3.1 ± 1.3 3.4 ± 1.1 3.2 ± 1.1
Patients with MADRS total score ≥20
‡ 3.9 ± 0.9 3.8 ± 0.9 3.8 ± 0.8
Patients with CGI-BP-D severity score ≥4
§ 4.4 ± 0.6 4.3 ± 0.5 4.2 ± 0.4
Discontinuations, n (%)
Patients with mixed episodes,
† overall 44 (39.6) 24 (35.8) 31 (25.0)
Adverse events 12 (10.8) 1 (1.5) 7 (5.6)
Lack of efficacy 8 (7.2) 8 (11.9) 7 (5.6)
Lost to follow-up 2 (1.8) 1 (1.5) 6 (4.8)
Withdrew consent 20 (18.0) 12 (17.9) 11 (8.9)
Other 2 (1.8) 2 (3.0) 0 (0)
Patients with MADRS total score ≥20,
‡ overall 19 (42.2) 11 (33.3) 13 (24.1)
Adverse events 6 (13.3) 1 (3.0) 2 (3.7)
Lack of efficacy 2 (4.4) 5 (15.2) 7 (13.0)
Lost to follow-up 2 (4.4) 0 (0) 1 (1.9)
Withdrew consent 8 (17.8) 4 (12.1) 3 (5.6)
Other 1 (2.2) 1 (3.0) 0 (0)
Patients with CGI-BP-D severity score ≥4,
§ overall 26 (44.1) 14 (37.8) 19 (25.7)
Adverse events 6 (10.2) 1 (2.7) 4 (5.4)
Lack of efficacy 4 (6.8) 4 (10.8) 8 (10.8)
Lost to follow-up 1 (1.7) 1 (2.7) 3 (4.1)
Withdrew consent 13 (22.0) 7 (18.9) 4 (5.4)
other 2 (3.4) 1 (2.7) 0 (0)
CGI-BP-D = Clinical Global Impression for Bipolar Disorder-Depression scale; MADRS = Montgomery-Asberg Depression Rating Scale.
*Total number of patients in the randomized treatment group in the original studies.
†Based on diagnosis at baseline (not post hoc assessment of MADRS or CGI-BP-D score)
‡Data represent patients with a MADRS total score ≥20 regardless of baseline CGI-BP-D severity score.
§Data represent patients with a CGI-BP-D severity score ≥4 at baseline regardless of baseline MADRS total score.
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remission rates
In patients with baseline MADRS total scores ≥20,
MADRS remission rates (defined as MADRS total score
≤12) with asenapine were significantly greater than pla-
cebo on days 7 (57% vs 17%; P =0 . 0 0 4 )a n d2 1( 7 0 %v s
33%; P = 0.012); remission rate with asenapine on day 7
was significantly greater than olanzapine (57% vs 25%; P
= 0.006) and showed a trend towards statistical signifi-
cance on day 21 (70% vs 48%; P = 0.066). Remission
rates with olanzapine on days 7 (25%) and 21 (48%)
were not statistically different from placebo (P = 0.478
and P = 0.288, respectively; Figure 2A).
In patients with baseline CGI-BP-D severity score ≥4,
MADRS remission rates with asenapine were signifi-
cantly greater than placebo on day 7 (68% vs 35%; P =
0.014) and showed a trend towards statistical signifi-
cance on day 21 (68% vs 41%; P = 0.05); the remission
rate with asenapine on day 7 was significantly greater
than olanzapine (68% vs 45%; P = 0.031). MADRS
Table 2 Summary of mean changes from baseline in depressive symptoms for randomized patients
Asenapine Placebo Olanzapine
Mean ± SD P value Mean ± SD P value Mean ± SD P value
MADRS total score
Patients with mixed episodes
at baseline
Baseline 16.7 ± 6.3 18.8 ± 7.3 16.9 ± 6.9
Change at day 7 -6.3 ± 6.5 <0.0001 -4.4 ± 8.0 0.0011 -4.9 ± 5.3 <0.0001
Change at day 21 -8.2 ± 7.6 <0.0001 -7.1 ± 8.2 <0.0001 -6.8 ± 7.0 <0.0001
Patients with MADRS total
score ≥20 at baseline*
Baseline 24.4 ± 3.5 25.8 ± 4.7 24.7 ± 4.4
Change at day 7 -11.0 ± 7.6 <0.0001 -4.7 ± 9.5 0.0255 -6.9 ± 6.7 <0.0001
Change at day 21 -12.9 ± 8.6 <0.0001 -8.4 ± 9.6 0.0007 -10.3 ± 8.8 <0.0001
Patients with CGI-BP-D
severity score ≥4 at baseline
†
Baseline 20.2 ± 6.9 22.2 ± 7.5 19.7 ± 7.2
Change at day 7 -7.5 ± 8.3 <0.0001 -4.1 ± 7.8 0.0188 -5.5 ± 5.2 <0.0001
Change at day 21 -9.8 ± 8.6 <0.0001 -6.9 ± 10.7 0.0064 -8.2 ± 6.5 <0.0001
CGI-BP-D severity score
Patients with mixed episodes
at baseline
Baseline 3.1 ± 1.3 3.4 ± 1.1 3.2 ± 1.1
Change at day 7 -0.6 ± 0.9 <0.0001 -0.4 ± 1.1 0.0377 -0.7 ± 0.8 <0.0001
Change at day 21 -1.0 ± 1.3 <0.0001 -0.8 ± 1.3 0.0004 -0.9 ± 1.1 <0.0001
Patients with MADRS total scores≥20 at baseline* Baseline 3.9 ± 0.9 3.8 ± 0.9 3.8 ± 0.8
Change at day 7 -1.0 ± 1.0 <0.0001 -0.3 ± 1.2 0.1754 -0.8 ± 0.7 <0.0001
Change at day 21 -1.5 ± 1.4 <0.0001 -0.7 ± 1.2 0.0228 -1.2 ± 1.2 <0.0001
Patients with CGI-BP-D
severity score ≥4 at baseline
†
Baseline 4.4 ± 0.6 4.3 ± 0.5 4.2 ± 0.4
Change at day 7 -1.2 ± 0.8 <0.0001 -0.6 ± 1.1 0.0127 -1.0 ± 0.9 <0.0001
Change at day 21 -1.7 ± 1.2 <0.0001 -1.2 ± 1.1 0.0001 -1.6 ± 1.1 <0.0001
PANSS Marder anxiety/depression factor score
Patients with mixed episodes at baseline Baseline 12.9 ± 3.6 13.5 ± 3.5 12.6 ± 3.6
Change at day 7 -2.2 ± 3.5 <0.0001 -1.5 ± 3.6 0.0125 -1.7 ± 2.7 <0.0001
Change at day 21 -3.4 ± 3.7 <0.0001 -3.0 ± 2.9 <0.0001 -2.8 ± 3.0 <0.0001
Patients with MADRS total
score ≥20 at baseline*
Baseline 14.4 ± 3.3 14.5 ± 2.7 14.7 ± 3.1
Change at day 7 -3.7 ± 3.6 <0.0001 -0.9 ± 2.4 0.0784 -1.8 ± 3.0 0.0004
Change at day 21 -4.9 ± 4.2 <0.0001 -2.4 ± 2.4 0.0002 -3.4 ± 3.7 <0.0001
Patients with CGI-BP-D
severity score ≥4 at baseline
†
Baseline 13.8 ± 3.7 14.5 ± 2.9 13.5 ± 3.7
Change at day 7 -2.8 ± 3.3 <0.0001 -1.1 ± 2.2 0.0243 -1.5 ± 3.2 0.001
Change at day 21 -3.2 ± 4.5 0.0003 -2.4 ± 2.8 0.0007 -3.2 ± 3.4 <0.0001
CGI-BP-D = Clinical Global Impression for Bipolar Disorder-Depression scale; MADRS = Montgomery-Asberg Depression Rating Scale; PANSS = Positive and
Negative Syndrome Scale.
P values are based on a two-sided t-test of within-subject mean changes from baseline.
*Data represent patients with a MADRS total score ≥20 regardless of baseline CGI-BP-D severity score.
†Data represent patients with a CGI-BP-D severity score ≥4 at baseline regardless of baseline MADRS total score.
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Page 5 of 16Figure 1 Least Squares (LS) Mean Changes in Baseline MADRS Total Score. (A) Patients with baseline MADRS total scores ≥20; (B) patients
with baseline CGI-BP-D severity scores ≥4; (C) patients with a mixed episode at baseline. CGI-BP-D = Clinical Global Impression for Bipolar
Disorder-Depression; MADRS = Montgomery-Asberg Depression Rating Scale. Error bars represent SE. *P < 0.05;
†P ≤ 0.01 vs placebo. **P < 0.05
vs olanzapine.
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Page 6 of 16Figure 2 MADRS Remission Rate. (A) Patients with baseline MADRS total scores ≥20; (B) patients with baseline CGI-BP-D severity scores ≥4; (C)
patients with a mixed episode at baseline. CGI-BP-D = Clinical Global Impression for Bipolar Disorder-Depression scale; MADRS = Montgomery-
Asberg Depression Rating Scale. *P < 0.05;
†P ≤ 0.01;
‡P ≤ 0.001 vs placebo. **P < 0.05;
††P ≤ 0.01 vs olanzapine.
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different from placebo on day 7 (45% vs 35%; P = 0.423)
but was significantly greater on day 21 (69% vs 41%; P =
0.027) (Figure 2B).
In patients with a mixed episode at baseline, MADRS
remission rates with asenapine were significantly greater
than placebo on days 7 (76% vs 44%; P <0 . 0 0 1 )a n d2 1
(78% vs 56%; P = 0.019); the remission rate with asena-
pine on day 7 was significantly greater than olanzapine
(76% vs 55%; P = 0.007). Remission rates with olanza-
pine were not significantly different from placebo on
day 7 (55% vs 44%; P = 0.259) but was significantly
higher with olanzapine on day 21 (74% vs 56%; P =
0.04) (Figure 2C).
Clinical Global Impression for Bipolar Disorder-Depression
Severity Scale score
In patients with baseline MADRS total scores ≥20, LS
mean ± SE changes from baseline in CGI-BP-D severity
scores with asenapine were significantly greater than
placebo on days 7 (-1.0 ± 0.2 vs -0.4 ± 0.2; P = 0.011)
and 21 (-1.4 ± 02 vs -0.7 ± 0.2; P = 0.020) but did not
differ statistically from olanzapine on either day 7 (P =
0.320) or 21 (P = 0.622). Changes with olanzapine ver-
sus placebo showed a trend towards statistical signifi-
cance on day 7 (-0.8 ± 0.1 vs -0.4 ± 0.2; P = 0.062) and
were significantly greater versus placebo on day 21 (-1.3
± 0.2 vs -0.7 ± 0.2; P = 0.038) (Figure 3A).
In patients with baseline CGI-BP-D severity scores ≥4,
LS mean ± SE changes in CGI-BP-D severity scores
with asenapine were significantly greater than placebo
o nd a y7( - 1 . 2±0 . 2v s- 0 . 6±0 . 2 ;P = 0.015) but not
day 21 (-1.6 ± 0.2 vs -1.2 ± 0.23; P = 0.194) and did not
differ statistically from olanzapine on either day 7 (P =
0.463) or 21 (P = 0.572). Changes with olanzapine were
significantly greater than placebo on day 7 (-1.0 ± 0.1 vs
-0.6 ± 0.2; P = 0.047) and showed a trend towards statis-
tical significance on day 21 (-1.7 ± 0.2 vs -1.2 ± 0.2; P =
0.057) (Figure 3B).
In patients with a mixed episode at baseline, LS mean
± SE changes in CGI-BP-D severity score with asenapine
were significantly greater than placebo on day 7 (-0.7 ±
0.1 vs -0.3 ± 0.1; P = 0.008) and approached significance
on day 21 (-1.0 ± 0.1 vs -0.7 ± 0.2; P = 0.089); asenapine
and olanzapine did not differ on either day 7 (P = 0.968)
or 21 (P = 0.543). Changes with olanzapine were signifi-
cantly greater than placebo on day 7 (-0.7 ± 0.1 vs -0.3
±0 . 1 ;P = 0.006) but not on day 21 (-0.9 ± 0.1 vs -0.7 ±
0.2; P = 0.203) (Figure 3C).
Mean ± SD changes from baseline CGI-BP-D severity
scores are summarized in Table 2. Within-subject
changes from baseline on days 7 and 21 were statisti-
cally significant in all treatment groups and across all
depression-related categories, with 1 exception. Change
in CGI-BP-D score on day 7 in patients with MADRS
≥20 treated with placebo was not statistically significant.
Positive and Negative Syndrome Scale Marder Anxiety/
Depression Factor score
In patients with baseline MADRS total scores ≥20, LS
mean ± SE changes from baseline in PANSS Marder
anxiety/depression factor scores with asenapine were
significantly greater than placebo on days 7 (-3.7 ± 0.6
vs -1.0 ± 0.6; P = 0.001) and 21 (-4.8 ± 0.7 vs -2.3 ± 0.7;
P = 0.011) and greater than olanzapine on day 7 (-3.7 ±
0.6 vs -1.7 ± 0.4; P = 0.006). Changes with olanzapine
( - 1 . 7±0 . 4o nd a y7a n d- 3 . 5±0 . 5o nd a y2 1 )d i dn o t
statistically differ from placebo (P = 0.310 and 0.179;
Figure 4A).
In patients with baseline CGI-BP-D severity scores ≥4,
LS mean ± SE changes in PANSS Marder anxiety/
depression factor scores with asenapine were signifi-
cantly greater than placebo on day 7 (-2.7 ± 0.4 vs -0.7
±0 . 6 ;P = 0.005) but not day 21 (-3.1 ± 0.6 vs -1.8 ±
0.7; P = 0.139) and showed a trend towards statistical
significance versus olanzapine on day 7 (-2.7 ± 0.4 vs
-1.7 ± 0.4; P = 0.066) but not on day 21 (-3.1 ± 0.6 vs
-3.5 ± 0.4; P = 0.647). Changes with olanzapine were
not significantly different from placebo on day 7 (-1.7 ±
0.4 vs -0.7 ± 0.6; P = 0.133) but were significantly
greater on day 21 (-3.5 0.4 vs -1.8 ± 0.7; P =0 . 0 4 8 )
(Figure 4B).
In patients with a mixed episode, LS mean ± SE
changes in PANSS Marder anxiety/depression scores
with asenapine were significantly greater than placebo
o nd a y7( - 2 . 2±0 . 3v s- 1 . 0±0 . 4 ;P = 0.031) but not
day 21 (-3.4 ± 0.4 vs -2.5 ± 0.5; P = 0.129); changes with
asenapine and olanzapine did not differ on either day 7
(P =0 . 4 7 1 )o r2 1( P = 0.473). Changes with olanzapine
( - 1 . 9±0 . 3a td a y7a n d- 3 . 1±0 . 3a td a y2 1 )w e r en o t
statistically different from placebo (P = 0.105 and 0.331,
respectively; Figure 4C).
Mean ± SD changes from baseline PANSS Marder
anxiety/depression factor score are summarized in Table
2. With only 1 exception (change in PANSS Marder
anxiety/depression factor score on day 7 in patients with
MADRS ≥20 treated with placebo were not statistically
significant), within-subject changes from baseline on
days 7 and 21 were statistically significant in all treat-
ment groups and across all depression-related
categories.
Discussion
In this exploratory post hoc analysis, asenapine was sta-
tistically superior to placebo in decreasing depressive
symptoms in bipolar I disorder patients who were
experiencing acute manic or mixed episodes and had
clinically relevant depressive symptoms at baseline.
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Page 8 of 16Figure 3 Least Squares (LS) Mean Changes in Baseline CGI-BP-D Severity Score. (A) Patients with baseline MADRS total scores ≥20; (B)
patients with baseline CGI-BP-D severity scores ≥4; (C) patients with a mixed episode at baseline. CGI-BP-D = Clinical Global Impression for
Bipolar Disorder-Depression scale; MADRS = Montgomery-Asberg Depression Rating Scale. Error bars represent SE. *P < 0.05;
†P ≤ 0.01 vs
placebo.
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Page 9 of 16Figure 4 Least Squares (LS) Mean Changes in Baseline PANSS Marder Anxiety/Depression Factor Score. (A) Patients with baseline MADRS
total scores ≥20; (B) patients with baseline CGI-BP-D severity scores ≥4; (C) patients with a mixed episode at baseline. CGI-BP-D = Clinical Global
Impression for Bipolar Disorder-Depression scale; MADRS = Montgomery-Asberg Depression Rating Scale; PANSS = Positive and Negative
Syndrome Scale. Error bars represent SE. *P < 0.05;
†P ≤ 0.01;
‡P ≤ 0.001 vs placebo.
††P ≤ 0.01 vs olanzapine.
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Page 10 of 16Improvement was seen in all depression endpoints
(change from baseline on MADRS total score, CGI-BP-
D severity score, and PANSS Marder anxiety/depression
factor score), as well as on MADRS remission rate.
These results are based on analyses using observed cases
at selected visits. To address the issue of missing data
associated with early study discontinuation, study end-
point (using LOCF) were also reviewed. The LOCF
results were in line with those reported from the
observed case analysis.
The efficacy of asenapine in treating depressive symp-
toms is supported by in vitro and in vivo preclinical
findings. Asenapine has a complex receptor signature,
which includes combined antagonism at serotonergic (5-
HT2A and 5-HT2C ) and adrenergic (a2) receptors;[10]
antagonism of these receptor subtypes has been linked
to the amelioration of depressive symptoms[18,19].
Further, asenapine stimulates release of cortical dopa-
mine, noradrenaline, and serotonin [20] and exerts an
antidepressant-like effect in animal models[13].
Although various atypical antipsychotics have been
evaluated for treatment of depressive episodes associated
with bipolar disorder, the efficacy of these agents has
varied substantially (see Table 3 for a summary of pub-
lished results); currently only olanzapine in combination
with fluoxetine and quetiapine monotherapy are
approved by the US Food and Drug Administration for
the treatment of bipolar depression [8,9]. In patients
with bipolar depression, olanzapine alone and olanza-
pine in combination with fluoxetine significantly
decreased MADRS total scores; placebo-corrected
reductions over 3 to 8 weeks of treatment ranged from
3.1-4.4 points with olanzapine alone (versus 1.4-3.6
points for olanzapine alone in the studies included in
this analysis) and 5.9-7.8 points when combined with
fluoxetine [21]. In the current analysis, olanzapine also
tended to improve depressive symptoms, but the olanza-
pine data appeared to be less consistent than those of
asenapine. Additionally, asenapine was statistically
superior to olanzapine in several instances (eg, day 7
change in MADRS and PANSS Marder anxiety/depres-
sion scores and MADRS remission rate). In the BipOLar
DEpRession (ie, BOLDER) trials, quetiapine monother-
apy significantly reduced MADRS total score compared
with placebo, with placebo-corrected reductions in
MADRS total scores of 4-5 points at week 3 and 4-6
points at week 8 reported in patients with bipolar I or II
depression [22,23].
Despite being approved for adjunctive use in the treat-
ment of major depressive disorder [24], aripiprazole was
no more effective than placebo in alleviating depressive
symptoms at endpoint in patients with bipolar I disorder
[25]. Risperidone as an adjunct to mood stabilizer treat-
ment was associated with a recovery rate of only 5% in
an open-label trial of treatment-resistant patients with
bipolar I or II disorder experiencing depressive episodes
[26]. Ziprasidone was effective in the treatment of bipo-
lar II disorder patients experiencing major depressive
episodes in an open-label trial [27] and in treating
depressive symptoms in a post hoc analysis of bipolar
patients experiencing dysphoric mania [28]; however,
reviews indicate that ziprasidone was not superior to
placebo in controlled studies of patients with bipolar
depression [6,29].
Although direct comparisons between this exploratory
post hoc analysis and randomized clinical trials should
be made cautiously, the placebo-corrected changes in
MADRS total score in the current analysis (asenapine,
2.6-6.6 points; olanzapine, 1.4-3.6 points) are in the
same range as those previously reported in patients with
bipolar I or II depression receiving quetiapine or in
patients with bipolar I depression receiving olanzapine/
fluoxetine [21-23]. They are also within the range of
values reported in a meta-analysis of controlled bipolar
depression trials of quetiapine, olanzapine, and aripipra-
zole, which reported overall mean MADRS total score
reductions of 3.91 points (95% CI, -5.55 to -2.26) versus
placebo; this value increased to 4.90 points (95% CI,
-6.21 to -3.59) when negative aripiprazole trials were
excluded [30].
In this post hoc analysis, differential effects were
observed among depression-related categories, with
reductions in depressive symptoms being more robust
in patients with baseline MADRS total scores ≥20 than
in those with baseline CGI-BP-D severity scores of ≥4
or those experiencing a mixed episode. This variation
might result from the rating scales used. Although a
MADRS total score of 20 and CGI-BP-D severity score
of 4 corresponds to moderate depressive symptoms
[31,32], respectively, the CGI-BP-D may be less sensitive
to change than the MADRS, reducing the ability to
detect depressive symptom changes in patients with
baseline CGI-BP-D severity score ≥4 (on a 7-point scale)
versus in those with a baseline MADRS total scores ≥20
(on a 60-point scale). Comparisons with patients experi-
encing a mixed episode for the purposes of this post
hoc analysis could also be problematic. Due to the
higher overall level of variability in baseline depressive
symptoms in patients with mixed episodes, the possibi-
lity of detecting statistically significant changes in this
post hoc analysis may have been compromised.
Conclusions
Depression is considered the predominant burden of
bipolar disorder, with depressive states accounting for
about 75% of the typical unwell time in bipolar I and
II disorder [6]. Therefore, additional effective treat-
ment options are needed for bipolar patients with
Szegedi et al. BMC Psychiatry 2011, 11:101
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Page 11 of 16Table 3 Efficacy of selected antipsychotics for depressive symptoms in bipolar disorder: Summary of selected studies
MADRS Total Score CGI-BP-D
Study Design Baseline Change From
Baseline
MADRS
Remitters*
Baseline Change From
Baseline
Asenapine
(current
post hoc
analysis)
Design: randomized, double-blind, placebo- and olanzapine-
controlled study in bipolar I disorder patients experiencing manic or
mixed episodes
Baseline
MADRS total
score ≥20
Asenapine:
24.0 ± 3.5
Olanzapine:
25.0 ± 4.4
Placebo: 26.0
± 4.7
LS mean ± SE at day 21
Baseline MADRS total
score ≥20
Asenapine: -13.6 ± 1.6
(P = 0.009 vs placebo)
Olanzapine: -10.6 ± 1.3
Placebo: -7.0 ± 1.8
Percentage at day 21
Baseline MADRS total
score ≥20
Asenapine: 70%
(P = 0.01 vs placebo)
Olanzapine: 48%
Placebo: 33%
total score
≥20 and CGI-
BP-D
severity score
≥4Asenapine:
3.9 ± 0.9
Olanzapine:
3.8 ± 0.8
Placebo: 3.8 ±
0.9
LS mean ± SE at day 21
Baseline MADRS total
score ≥20
Asenapine: -1.4 ± 0.2
(P = 0.020 vs placebo)
Olanzapine: -1.3 ± 0.2
(P = 0.038 vs placebo)
Placebo: -0.7 ± 0.2
Duration: 3 wk Baseline CGI-
BP-D severity
score ≥4
Asenapine:
20.0 ± 6.9
Olanzapine:
20.0 ± 7.2
Placebo: 22.0
± 7.5
Baseline CGI-BP-D severity
score ≥4
Asenapine: -9.9 ± 1.3
(P = 0.030 vs placebo)
Olanzapine: -8.8 ± 1.0
Placebo: -5.4 ± 1.6
Baseline CGI-BP-D
severity score ≥4
Asenapine: 67%
Olanzapine: 69%
(P = 0.026 vs
placebo)
Placebo: 41%
Baseline CGI-
BP-D severity
score ≥4
Asenapine: 4.4
± 0.6
Olanzapine:
4.2 ± 0.5
Placebo: 4.3 ±
0.5
Baseline CGI-BP-D
severity score ≥4
Asenapine: -1.6 ± 0.2
Olanzapine: -1.7 ± 0.2
Placebo: -1.2 ± 0.2
Treatment:
Asenapine 5-10 mg BID
Olanzapine 5-20 mg QD
Placebo
Mixed episode
at baseline
Asenapine:
17.0 ± 6.3
Olanzapine:
17.0 ± 6.9
Placebo: 19.0
± 7.4
Mixed episode at
baseline
Asenapine: -8.5 ± 0.8
(P = 0.040 vs placebo)
Olanzapine: -7.2 ± 0.7
Placebo: -5.8 ± 1.1
Mixed episode at
baseline
Asenapine: 77%
(P = 0.026 vs
placebo)
Olanzapine: 74% (P =
0.036 vs placebo)
Placebo: 56%
Mixed episode
at baseline
Asenapine: 3.1
± 1.3
Olanzapine:
3.2 ± 1.1
Placebo: 3.4 ±
1.1
Mixed episode at
baseline
Asenapine: -1.0 ± 0.1
Olanzapine:-0.9 ± 0.1
Placebo:-0.7 ± 0.2
Aripiprazole
Thase et al
[22]
Design: randomized, double-blind, placebo-controlled study in
bipolar I disorder patients experiencing a major depressive episode
without psychotic features
Aripiprazole:
29.1
Placebo: 28.5
Adjusted mean ± SE at
week 8
Not significant vs
placebo (actual change
not reported)
Percentage at week 8
Aripiprazole: 30%
Placebo: 28%
Aripiprazole:
4.3
Placebo: 4.3
Adjusted mean ± SE at
week 8
Not significant vs
placebo (actual change
not reported)
Duration: 8 wk
Treatment:
Aripiprazole 5-30 mg (n = 186)
Placebo (n = 188)
Thase et al
[22]
Design: randomized, double-blind, placebo-controlled study in
bipolar I disorder patients experiencing a major depressive episode
without psychotic features
Aripiprazole:
29.6
Placebo: 29.4
Adjusted mean ± SE at
week 8
Not significant vs
placebo (actual change
not reported)
Percentage at week 8
Aripiprazole: 26%
Placebo: 29%
Aripiprazole:
4.4
Placebo: 4.5
Adjusted mean ± SE at
week 8
Not significant vs
placebo (actual change
not reported)
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6Table 3 Efficacy of selected antipsychotics for depressive symptoms in bipolar disorder: Summary of selected studies (Continued)
Duration: 8 wk
Treatment:
Aripiprazole 5-30 mg (n = 187)
Placebo (n = 188)
Olanzapine &
olanzapine-
fluoxetine
Tohen et al
[18]
Design: randomized, double-blind, placebo-controlled study in
bipolar I disorder patients with
MADRS total score ≥20
Olanzapine:
32.6
Olanzapine-
fluoxetine:
30.8
Placebo: 31.3
Mean ± SE at week 8
Olanzapine: -15.0 ± 0.7
(P = 0.002 vs placebo)
Olanzapine-fluoxetine:
-18.5 ± 1.3
(P < 0.001 vs placebo)
Placebo: -11.9 ± 0.8
Percentage at week 8
Olanzapine: 33% (P =
0.02 vs placebo)
Olanzapine-fluoxetine:
49% (P < 0.001 vs
placebo)
Placebo: 25%
Olanzapine:
4.9 ± 0.8
Olanzapine-
fluoxetine: 4.8
± 0.7
Placebo: 4.8 ±
0.8
Mean ± SE at week 8
Olanzapine: -1.6 ± 0.1 (P
= 0.004 vs placebo)
Olanzapine-fluoxetine:
-2.2 ± 0.2
(P < 0.001 vs placebo)
Placebo:-1.2 ± 0.1
Duration: 8 wk
Treatment:
Olanzapine 5-20 mg (n = 370)
Olanzapine-fluoxetine 6-12 mg and 25-50 mg (n = 86)
Placebo (n = 377)
Quetiapine
Thase et al
[20]
Design: randomized, double-blind, placebo-controlled in bipolar I or II
disorder patients experiencing a major depressive episode
Quetiapine
300 mg: 31.1
± 5.7
Quetiapine
600 mg: 29.9
± 5.6
Placebo: 29.6
± 5.4
LS mean ± SE at last
assessment
Quetiapine 300 mg:
-16.9 ± 1.0
(P < 0.001 vs placebo)
Quetiapine 600 mg:
-16.0 ± 1.0
(P = 0.001 vs placebo)
Placebo: -11.9 ± 1.0
Percentage at last
assessment
Quetiapine 300 mg:
52%
(P < 0.05 vs placebo)
Quetiapine 600 mg:
52%
(P < 0.01 vs placebo)
Placebo: 37%
NA NA
Duration: 8 wk
Treatment:
Quetiapine 300 mg (n = 172)
Quetiapine 600 mg (n = 169)
Placebo (n = 168)
Calabrese et
al[19]
Design: randomized, double-blind, placebo-controlled in bipolar I or II
disorder patients
experiencing a major depressive episode
Quetiapine
300 mg: 30.4
± 5.0
Quetiapine
600 mg: 30.3
± 5.3
Placebo: 30.6
± 5.3
Mean at last assessment
Quetiapine 300 mg:
-16.4
(P < 0.001 vs placebo)
Quetiapine 600 mg:
-16.7
(P < 0.001 vs placebo)
Placebo: -10.3
Percentage at last
assessment
Quetiapine 300 mg:
53%
(P < 0.001 vs
placebo)
Quetiapine 600 mg:
53%
(P < 0.001 vs
placebo)
Placebo: 28%
NA NA
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6Table 3 Efficacy of selected antipsychotics for depressive symptoms in bipolar disorder: Summary of selected studies (Continued)
Duration: 8 wk
Treatment:
Quetiapine 300 mg (n = 181)
Quetiapine 600 mg (n = 180)
Placebo (n = 181)
Ziprasidone
Liebowitz et
al[24]
Design: open-label in bipolar II disorder patients experiencing a
major depressive episode
Ziprasidone:
28.5 ± 5.0
Mean change ± SD at
week 8
Ziprasidone: 13.2 ± 9.0
(P < 0.0001 vs baseline)
NA NA NA
Duration: 8 wk
Treatment:
Ziprasidone 20 mg QD -60 mg BID (n = 30)
BID = twice daily; CGI-BP-D = Clinical Global Impression for Bipolar Disorder-Depression scale; LS = least squares; MADRS = Montgomery-Asberg Depression Rating Scale; NA = not applicable; QD = once daily.
*For aripiprazole, defined as MADRS total score ≤8; for all others, defined as MADRS total score ≤12.
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6depressive symptoms. In these exploratory post hoc
analyses, asenapine reduced depressive symptoms in
bipolar I disorder patients experiencing acute manic or
mixed episodes with clinically-relevant depressive
symptoms at baseline. These data suggest asenapine
may be useful in the treatment of depressive episodes
associated with bipolar disorder. However, the results
of these analyses need to be interpreted in light of the
fact that the primary study population was diagnosed
with manic or mixed episodes rather than acute bipo-
lar depression at the time of study entry. Furthermore,
because these analyses were performed in a subset of
patients from the original trials, the sample size for
this post hoc analysis is small and not necessarily
representative of the target population. Prospective
controlled clinical trials in patients with bipolar
depression are needed to definitively demonstrate the
efficacy of asenapine in the treatment of depressive
symptoms in bipolar disorder.
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